Results 71 to 80 of about 5,752,243 (395)

Multiple Myeloma : an update on disease biology and therapy [PDF]

, 2004
Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Cook, Rachel J., Dingli, David
core  

Ixazomib for relapsed or refractory multiple myeloma : review from an evidence review group on a NICE single technology appraisal [PDF]

, 2018
Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide plus dexamethasone (IXA-LEN-DEX) and licensed for relapsed or refractory multiple myeloma.
Armoiry, Xavier, Clarke, Aileen, Connock, M., Cummins, Ewen, Melendez-Torres, G. J., Royle, Pamela, Tsertsvadze, Alexander   +6 more
core   +1 more source

Possible role of human ribonuclease dicer in the regulation of R loops

FEBS Open Bio, EarlyView.
R loops play an important role in regulating key cellular processes such as replication, transcription, centromere stabilization, or control of telomere length. However, the unscheduled accumulation of R loops can cause many diseases, including cancer, and neurodegenerative or inflammatory disorders. Interestingly, accumulating data indicate a possible
Klaudia Wojcik, Paulina Krzeminska, Anna Kurzynska‐Kokorniak   +2 more
wiley   +1 more source

BCMA-targeted immunotherapy for multiple myeloma

Journal of Hematology & Oncology, 2020
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen
Bo Yu, Tianbo Jiang, Delong Liu
semanticscholar   +1 more source

Matrix: a complex amalgam of structures and functions in tumor microenvironment

FEBS Open Bio, EarlyView.
The matrix is a dynamic, intricate three‐dimensional mesh of biomolecules with both structural and functional properties. This review deals with the complexity of this ‘molecular amalgam’ in the tumor microenvironment and highlights its importance in the maintenance and evolution of tumors by describing certain matrix biomolecules, such as ...
Spyros S. Skandalis, Evgenia Tsoukala, Theodora D. Sarantopoulou, Maria‐Elpida Christopoulou   +3 more
wiley   +1 more source

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Frontiers in Immunology, 2018
Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years.
Yu-Tzu Tai, Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Kenneth C. Anderson   +4 more
doaj   +1 more source

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry [PDF]

, 2016
Spanish Myeloma Group (GEM) and Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups: et al.Multiple myeloma remains largely incurable.
Blanco, Juan F., Fernández, Carlos, García-Sanz, Ramón, Gutiérrez, Norma Carmen, Lahuerta, Juan José, Lécrevisse, Quentin, Martínez-López, Joaquín, Mateos, Maria Victoria, Ocio, Enrique M., Orfao, Alberto, Paiva, Bruno, Pessoa de Magalhães, Roberto J., Pérez-Andrés, Martin, San Miguel, Jesús F., Sobral da Costa, E., Vidriales, Maria Belén   +15 more
core   +1 more source

Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

Advanced Functional Materials, EarlyView.
This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley   +1 more source

Single-cell analysis of the CD8⁺ T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69^- subset suggesting potent cytotoxic effectors exist within the tumor bed

Haematologica, 2023
Multiple myeloma (MM) is an incurable disease of the bone marrow (BM) characterized by the uncontrolled proliferation of neoplastic plasma cells. While CD8+ T cells have an established role in disease control, few studies have focused on these cells ...
James Favaloro, Christian E. Bryant, Edward Abadir, Samuel Gardiner, Shihong Yang, Tracy King, Najah Nassif, Lisa M. Sedger, Richard Boyle, Douglas E. Joshua, P. Joy Ho   +10 more
doaj   +1 more source

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Journal of Clinical Investigation, 2019
BACKGROUND Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM).
Adam D. Cohen, A. Garfall, E. Stadtmauer, J. Melenhorst, S. Lacey, E. Lancaster, D. Vogl, Brendan M. Weiss, Karen Dengel, A. Nelson, G. Plesa, Fang Chen, M. Davis, W. Hwang, R. Young, J. Brogdon, R. Isaacs, Iulian Pruteanu-Malinici, Don L. Siegel, Bruce L. Levine, Carl H. June, Michael C. Milone   +21 more
semanticscholar   +1 more source